Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
CVKD Form 4 activity by transaction type, last 90 days
Form 4 transaction type
Transactions
Shares
Total value
Grant or award
5
575,000
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CVKD insider transactions (Form 4)
51
29 Form 4 filings on record, the earliest from Aug 27, 2025, newest first.
Footnote F1 (shares): The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9… Full note on SEC EDGAR
Footnote F1 (shares): The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9… Full note on SEC EDGAR
Footnote F1 (shares): The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9… Full note on SEC EDGAR
Footnote F1 (shares): The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9… Full note on SEC EDGAR
Footnote F1 (shares): The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.51 through $3.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 through $3.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.04 through $3.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.14 through $3.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.09 through $4.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 through $4.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.22 through $3.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.20 through $4.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.03 through $4.34. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.20 through $4.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 through $4.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 through $4.47. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.25 through $4.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 through $5.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.40 through $4.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.47 through $6.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F4 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 through $5.535. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F5 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.81 through $5.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.60 through $5.82. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and… Full note on SEC EDGAR
Footnote F1 (price): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 18, 2025, in multiple transactions at prices ranging from $6.83 through $7.37, inclusive, having a… Full note on SEC EDGAR
Footnote F1 (shares): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025.
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.10. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 through $14.00. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the… Full note on SEC EDGAR
Footnote F1 (price): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on May 9, 2025.
Footnote F1 (price): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.11, inclusive, having a weighted average price as shown in column 4 of $14.02. The… Full note on SEC EDGAR
Footnote F2 (price): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.33, inclusive, having a weighted average price as shown in column 4 of $14.15. The… Full note on SEC EDGAR
Footnote F1 (price): Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $14.04 through $14.27, inclusive, having a weighted average price as shown in column 4 of $14.13. The… Full note on SEC EDGAR
An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
Cadrenal Therapeutics, Inc. (CVKD) had 5 insider filings in the last 90 days, with the most recent on 13 October 2026. The full record for CVKD runs to 29 Form 4 filings, the earliest from 27 August 2025. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CVKD stock?
No insider purchases of CVKD were filed in the last 90 days.
How many insiders are selling CVKD stock?
No insider sales of CVKD were filed in the last 90 days. 45 sales are on record for this company.
Where can I see CVKD SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CVKD Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Quang X. Pham - OfficerOpen-market sale$22K
Glynn Wilson - Director
Matthew K. Szot - Officer
